Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1276454

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1276454

North America Motion Sickness Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Antihistamines, Anticholinergics and Others), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2029

PUBLISHED:
PAGES: 76 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Multi User License)
USD 1800
PDF (Corporate User License)
USD 2520

Add to Cart

The North America Motion Sickness Treatment Market would witness market growth of 2.5% CAGR during the forecast period (2023-2029).

The market's growth is anticipated to be propelled by untapped, emerging markets with high potential, owing to the presence of enhanced healthcare infrastructure, rising unmet healthcare demands, and a surge in need for efficient motion sickness medication.

Furthermore, certain demographics may be more susceptible to motion sickness symptoms, such as expectant mothers and individuals between the ages of 2 and 12. The initial indications of motion sickness encompass queasiness, heightened salivation, burping, perspiration, hyperventilation, and a general sense of discomfort. Motion sickness can be prevented or treated through pharmacological therapies such as anticholinergic drugs, antihistaminic drugs, and various other medications.

The North American over-the-counter drugs sector is experiencing growth due to the rising trend of individuals choosing OTC drugs for minor complications instead of seeking intensive treatment from healthcare professionals. This trend is particularly prevalent in countries such as the U.S., Canada, and Mexico. Furthermore, the emergence of numerous mid-size and small players in the region has led to the introduction of innovative medications at reduced prices, thereby enhancing the over-the-counter drugs sector in the region. The wider usage of OTC, like antihistamines, by general consumers for various minor health issues like motion sickness is expected to propel the motion sickness treatment market growth in the region.

The US market dominated the North America Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $131.6 Million by 2029. The Canada market is poised to grow at a CAGR of 4.5% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 4.3% during (2023 - 2029).

Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Antihistamines
  • Anticholinergics
  • Others

By Route of Administration

  • Oral
  • Others

By Distribution Channel

  • Drug Store & Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled

  • Viatris, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Baxter International, Inc.
  • Novartis AG
  • Abbott Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Prestige Consumer Healthcare, Inc.
  • WellSpring Pharmaceutical Corporation (Avista Capital Partners)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 North America Motion Sickness Treatment Market, by Drug Class
    • 1.4.2 North America Motion Sickness Treatment Market, by Route of Administration
    • 1.4.3 North America Motion Sickness Treatment Market, by Distribution Channel
    • 1.4.4 North America Motion Sickness Treatment Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition & scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. North America Motion Sickness Treatment Market by Drug Class

  • 3.1 North America Antihistamines Market by Country
  • 3.2 North America Anticholinergics Market by Country
  • 3.3 North America Others Market by Country

Chapter 4. North America Motion Sickness Treatment Market by Route of Administration

  • 4.1 North America Oral Market by Country
  • 4.2 North America Others Market by Country

Chapter 5. North America Motion Sickness Treatment Market by Distribution Channel

  • 5.1 North America Drug Store & Retail Pharmacies Market by Country
  • 5.2 North America Hospital Pharmacies Market by Country
  • 5.3 North America Online Pharmacies Market by Country

Chapter 6. North America Motion Sickness Treatment Market by Country

  • 6.1 US Motion Sickness Treatment Market
    • 6.1.1 US Motion Sickness Treatment Market by Drug Class
    • 6.1.2 US Motion Sickness Treatment Market by Route of Administration
    • 6.1.3 US Motion Sickness Treatment Market by Distribution Channel
  • 6.2 Canada Motion Sickness Treatment Market
    • 6.2.1 Canada Motion Sickness Treatment Market by Drug Class
    • 6.2.2 Canada Motion Sickness Treatment Market by Route of Administration
    • 6.2.3 Canada Motion Sickness Treatment Market by Distribution Channel
  • 6.3 Mexico Motion Sickness Treatment Market
    • 6.3.1 Mexico Motion Sickness Treatment Market by Drug Class
    • 6.3.2 Mexico Motion Sickness Treatment Market by Route of Administration
    • 6.3.3 Mexico Motion Sickness Treatment Market by Distribution Channel
  • 6.4 Rest of North America Motion Sickness Treatment Market
    • 6.4.1 Rest of North America Motion Sickness Treatment Market by Drug Class
    • 6.4.2 Rest of North America Motion Sickness Treatment Market by Route of Administration
    • 6.4.3 Rest of North America Motion Sickness Treatment Market by Distribution Channel

Chapter 7. Company Profiles

  • 7.1 Viatris, Inc.
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental Analysis
    • 7.1.4 Research & Development Expense
  • 7.2 Teva Pharmaceutical Industries Ltd.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 Amneal Pharmaceuticals, Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental Analysis
    • 7.3.4 Research & Development Expenses
  • 7.4 Baxter International, Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental Analysis
    • 7.4.4 Research & Development Expense
  • 7.5 Novartis AG
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expense
  • 7.6 Abbott Laboratories
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Segmental and Regional Analysis
    • 7.6.4 Research & Development Expense
    • 7.6.5 SWOT Analysis
  • 7.7 Sun Pharmaceutical Industries Ltd.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Regional Analysis
    • 7.7.4 Research & Development Expenses
  • 7.8 Zydus Lifesciences Ltd.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
    • 7.8.5 Recent strategies and developments:
      • 7.8.5.1 Trials and Approvals:
  • 7.9 Prestige Consumer Healthcare, Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Segmental and Regional Analysis
  • 7.10. WellSpring Pharmaceutical Corporation (Avista Capital Partners)
    • 7.10.1 Company Overview

LIST OF TABLES

  • TABLE 1 North America Motion Sickness Treatment Market, 2019 - 2022, USD Million
  • TABLE 2 North America Motion Sickness Treatment Market, 2023 - 2029, USD Million
  • TABLE 3 North America Motion Sickness Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 4 North America Motion Sickness Treatment Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 5 North America Antihistamines Market by Country, 2019 - 2022, USD Million
  • TABLE 6 North America Antihistamines Market by Country, 2023 - 2029, USD Million
  • TABLE 7 North America Anticholinergics Market by Country, 2019 - 2022, USD Million
  • TABLE 8 North America Anticholinergics Market by Country, 2023 - 2029, USD Million
  • TABLE 9 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 10 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 11 North America Motion Sickness Treatment Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 12 North America Motion Sickness Treatment Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 13 North America Oral Market by Country, 2019 - 2022, USD Million
  • TABLE 14 North America Oral Market by Country, 2023 - 2029, USD Million
  • TABLE 15 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 16 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 17 North America Motion Sickness Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 18 North America Motion Sickness Treatment Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 19 North America Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 20 North America Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 21 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 22 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 23 North America Online Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 24 North America Online Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 25 North America Motion Sickness Treatment Market by Country, 2019 - 2022, USD Million
  • TABLE 26 North America Motion Sickness Treatment Market by Country, 2023 - 2029, USD Million
  • TABLE 27 US Motion Sickness Treatment Market, 2019 - 2022, USD Million
  • TABLE 28 US Motion Sickness Treatment Market, 2023 - 2029, USD Million
  • TABLE 29 US Motion Sickness Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 30 US Motion Sickness Treatment Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 31 US Motion Sickness Treatment Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 32 US Motion Sickness Treatment Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 33 US Motion Sickness Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 34 US Motion Sickness Treatment Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 35 Canada Motion Sickness Treatment Market, 2019 - 2022, USD Million
  • TABLE 36 Canada Motion Sickness Treatment Market, 2023 - 2029, USD Million
  • TABLE 37 Canada Motion Sickness Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 38 Canada Motion Sickness Treatment Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 39 Canada Motion Sickness Treatment Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 40 Canada Motion Sickness Treatment Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 41 Canada Motion Sickness Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 42 Canada Motion Sickness Treatment Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 43 Mexico Motion Sickness Treatment Market, 2019 - 2022, USD Million
  • TABLE 44 Mexico Motion Sickness Treatment Market, 2023 - 2029, USD Million
  • TABLE 45 Mexico Motion Sickness Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 46 Mexico Motion Sickness Treatment Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 47 Mexico Motion Sickness Treatment Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 48 Mexico Motion Sickness Treatment Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 49 Mexico Motion Sickness Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 50 Mexico Motion Sickness Treatment Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 51 Rest of North America Motion Sickness Treatment Market, 2019 - 2022, USD Million
  • TABLE 52 Rest of North America Motion Sickness Treatment Market, 2023 - 2029, USD Million
  • TABLE 53 Rest of North America Motion Sickness Treatment Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 54 Rest of North America Motion Sickness Treatment Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 55 Rest of North America Motion Sickness Treatment Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 56 Rest of North America Motion Sickness Treatment Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 57 Rest of North America Motion Sickness Treatment Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 58 Rest of North America Motion Sickness Treatment Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 59 key information - Viatris, Inc.
  • TABLE 60 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 61 Key Information - Amneal Pharmaceuticals, INc.
  • TABLE 62 Key Information - Baxter International, Inc.
  • TABLE 63 Key Information - Novartis AG
  • TABLE 64 Key Information - Abbott Laboratories
  • TABLE 65 Key Information - Sun Pharmaceutical Industries Ltd.
  • TABLE 66 Key Information - Zydus Lifesciences Ltd.
  • TABLE 67 Key Information - Prestige consumer healthcare inc.
  • TABLE 68 Key Information - WellSpring Pharmaceutical Corporation

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Swot analysis: Abbott laboratories
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!